Publications

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma

Ho, W.J., Danilova, L., Lim, S.U.

Background and aims Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway have clinical activity in hepatocellular carcinoma (HCC), but only a subset of patients respond to these therapies, highlighting a need for novel biomarkers to improve clinical benefit. HCC usually occurs in the setting of liver cirrhosis from chronic hepatitis B or C viral infection, but the effects of viral status on the tumor immune microenvironment and clinical responses to ICIs in HCC remains unclear.

Citation

Ho, W.J., Danilova, L., Lim, S.U. "Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma" Journal for ImmunoTherapy of Cancer (2020): doi.org/10.1136/jitc-2019-000394